mojobeta

Vanda Holding Up Well

Vanda has a strong outlook indeed. My suspicion is that there are at least two suitors - probably one big pharma seeking to buy Vanda outright and another seeking to enter into a marketing partnership. Discussions have probably been on-going for at least a week and may reach a conclusion over the long weekend. On a point and figure chart Vanda counts to a target of $29.
Disclosure: I own Vanda common stock and the $7.50 call options expiring in January 2010.
Best - Mojobeta.